Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Summary by Relevant Sections Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's price point and revenue growth [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative of the class or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to inflated stock prices and subsequent losses for investors [1][3]. Company Overview - Lantheus Holdings, Inc. (NASDAQ: LNTH) is facing a federal securities class action with a deadline for lead plaintiff applications set for November 10, 2025 [1][6]. - The company has experienced significant stock price volatility, particularly following disappointing financial results related to Pylarify [4][5]. Financial Performance - Lantheus reported first-quarter results below market expectations on May 7, 2025, with Pylarify's performance notably underwhelming [4]. - On August 6, 2025, the company announced further disappointing results, revealing an 8.3% year-over-year decline in Pylarify's performance and a reduction in fiscal year 2025 growth projections [4]. Stock Market Reaction - Following the negative announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [5]. Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who can adequately represent the class [6]. - Faruqi & Faruqi encourages individuals with information regarding Lantheus' conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - The Lantheus class action lawsuit alleges that Lantheus Holdings, Inc. and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, leading to significant stock price declines following disappointing financial results [1][4][5][6]. Group 1: Lawsuit Details - The lawsuit, titled Margolis v. Lantheus Holdings, Inc., seeks to represent purchasers of Lantheus securities and claims violations of the Securities Exchange Act of 1934 [1]. - The complaint highlights that Lantheus's key product, Pylarify, is a PET imaging agent used for diagnosing and treating prostate cancer [3]. - Allegations include that Lantheus executives created a false impression of the company's revenue potential while downplaying risks from competition and market dynamics [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, and slashed fiscal year 2025 growth projections, causing the stock price to fall nearly 29% [6]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Lantheus securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [7]. - The lead plaintiff can select a law firm to litigate the case and does not need to be the lead plaintiff to share in any potential recovery [7]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [8].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Financial Performance - On May 7, 2025, Lantheus reported disappointing first-quarter financial results, with sales of its oncology product Pylarify decreasing year-over-year, leading to a reduction in full-year projections [4]. - Following this announcement, Lantheus's stock price dropped by $24.35, or 23.23%, closing at $80.49 per share [5]. - On August 6, 2025, the company announced second-quarter results that also missed expectations, with Pylarify sales falling by 8.3% year-over-year, prompting further reductions in growth expectations and full-year projections [6]. - The stock price fell again by $20.76, or 28.58%, closing at $51.87 per share after the second-quarter announcement [7].

Core Viewpoint - Lantheus (NASDAQ: LNTH) has seen a significant stock decline of 50% over the past year due to poor financial results, lowered guidance, and increased competition, which is viewed as a justified decline [1]. Company Performance - The company reported disappointing results that contributed to the stock's decline [1]. - Guidance for future performance has been reduced, indicating potential ongoing challenges [1]. Competitive Environment - The competitive landscape has become tougher for Lantheus, which may impact its market position and profitability [1].

Core Insights - Lantheus (NASDAQ: LNTH) has seen a 50% decline in stock price over the past year due to poor financial results, lowered guidance, and increased competition [1] Financial Performance - The company reported disappointing results which contributed to the stock price drop [1] - Guidance has been reduced, indicating potential challenges ahead for the company's financial outlook [1] Competitive Environment - The competitive landscape has become tougher, impacting Lantheus's market position and performance [1]

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-form-2/?id=171663&from=3 CLASS PERIO ...

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Allegations Against Lantheus - The lawsuit claims that Lantheus misled investors about the competitive position of PYLARIFY, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, which could jeopardize PYLARIFY's revenue and growth potential [2]. - The defendants' public statements are claimed to be materially false and misleading throughout the Class Period [2]. Group 2: Legal Process and Participation - Investors in Lantheus have until November 10, 2025, to seek appointment as lead plaintiff, representing the class in the lawsuit [3]. - A lead plaintiff is typically the investor or small group with the largest financial interest and is responsible for directing the litigation [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any recovery from the lawsuit [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Insights - Lantheus Holdings Inc. is currently viewed as a value stock, but has faced a downgrade from Goldman Sachs due to pricing pressures and slower uptake of Alzheimer's therapeutics [1][3] - The company reported Q2 2025 sales of $378.05 million, reflecting a year-over-year decline of 4.07% [2] - An exclusive licensing agreement was established with GE HealthCare for the prostate cancer imaging agent PYLARIFY, which will be developed and commercialized in Japan [2][3] - Lantheus's MK-6240 radiodiagnostic has shown promising results in pivotal studies for Alzheimer's disease, confirming its diagnostic capabilities [3][4] Financial Performance - Q2 2025 sales amounted to $378.05 million, marking a 4.07% decrease compared to the previous year [2] - The downgrade from Goldman Sachs included a price target reduction from $110 to $77 [1] Strategic Developments - Lantheus entered into an exclusive licensing agreement with GE HealthCare for PYLARIFY, aimed at enhancing prostate cancer diagnostics in Japan [2] - The company has made advancements in Alzheimer's diagnostics with MK-6240, which met its co-primary endpoints in clinical studies [3]